Ets-1 drives breast cancer cell angiogenic potential and interactions between breast cancer and endothelial cells.


Journal

International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042

Informations de publication

Date de publication:
01 2019
Historique:
received: 17 04 2018
accepted: 10 09 2018
pubmed: 27 10 2018
medline: 15 3 2019
entrez: 27 10 2018
Statut: ppublish

Résumé

Ets-1 transcription factor overexpression in breast cancers is associated with invasive features and is associated with a poor prognosis. Beyond its role in driving carcinoma cell invasion, in this study, we wished to determine whether Ets-1 overexpression in cancer cells promotes angiogenesis by creating a paracrine pro-invasive environment for endothelial cells as well. To address this question, we set up different co-culture models of cancer cells with endothelial cells. Conditioned media from cancer cells induced endothelial cell proliferation, migration and morphogenesis in matrix models. Of note, co-culture assays in three-dimensional matrix models also revealed the reciprocal induction of cancer cell morphogenesis by endothelial cells, in support of an angiocrine action on tumor cells. Ets-1 emerged as a key regulator of the angiogenic potential of breast cancer cells, favoring their ability to induce, in a paracrine manner, the morphogenesis of endothelial cells and also to physically interact with the latter. Nevertheless, Ets-1 overexpression in cancer cells also restrained their chemoattractive potential for endothelial cells both in Boyden chambers and in ex vivo 3D co-cultures. Finally, Ets-1 modulation in breast cancer cells qualitatively altered the angiogenic pattern of experimental in vivo tumors, with a balance between vessel recruitment and intratumoral small capillaries sprouting. Taken together, our data highlight a critical and intriguing role for Ets-1 in the angiogenic potential of breast cancer cells, and reveal another facet of Ets-1 oncogenic activities.

Identifiants

pubmed: 30365153
doi: 10.3892/ijo.2018.4605
pmc: PMC6254994
doi:

Substances chimiques

Culture Media, Conditioned 0
ETS1 protein, human 0
Proto-Oncogene Protein c-ets-1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-40

Références

Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncogene. 2000 Feb 10;19(6):762-72
pubmed: 10698494
Prostate. 2005 Jun 15;64(1):75-82
pubmed: 15651029
Lancet Oncol. 2015 Jun;16(6):656-66
pubmed: 25975632
Science. 2001 Oct 19;294(5542):530-1
pubmed: 11577202
Angiogenesis. 2009;12(3):267-74
pubmed: 19399631
Oncogene. 2003 Mar 27;22(12):1795-806
pubmed: 12660815
J Cell Physiol. 2008 Jun;215(3):782-93
pubmed: 18181172
FASEB J. 2004 Feb;18(2):326-8
pubmed: 14688196
J Pathol. 2015 Aug;236(4):491-504
pubmed: 25880038
J Cell Sci. 2003 Mar 15;116(Pt 6):1013-22
pubmed: 12584245
N Engl J Med. 1971 Nov 18;285(21):1182-6
pubmed: 4938153
J Pathol. 2001 May;194(1):43-50
pubmed: 11329140
Nature. 2015 Apr 16;520(7547):358-62
pubmed: 25855289
J Cell Sci. 2004 Apr 1;117(Pt 9):1847-57
pubmed: 15075244
Proc Natl Acad Sci U S A. 1993 Aug 15;90(16):7588-92
pubmed: 7689222
Oncogene. 2002 Dec 5;21(55):8506-9
pubmed: 12466970
Cell. 2007 Aug 24;130(4):601-10
pubmed: 17719539
Cell Struct Funct. 1991 Feb;16(1):87-93
pubmed: 2032312
J Pathol. 2003 Oct;201(2):173-80
pubmed: 14517833
Int J Cancer. 2014 Nov 15;135(10):2317-28
pubmed: 24706481
Clin Cancer Res. 2000 Jan;6(1):139-46
pubmed: 10656442
Cancer Treat Rev. 2017 Feb;53:98-110
pubmed: 28088074
Science. 2001 Oct 19;294(5542):564-7
pubmed: 11577200
Nature. 2011 May 19;473(7347):298-307
pubmed: 21593862
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Nat Rev Cancer. 2003 Jun;3(6):411-21
pubmed: 12778131
Eur J Cancer. 1996 Dec;32A(14):2438-50
pubmed: 9059332
Oncogene. 2007 Nov 22;26(53):7480-9
pubmed: 17563748
Int J Cancer. 2005 Apr 20;114(4):531-43
pubmed: 15609323
Sci Rep. 2016 Jan 14;6:19404
pubmed: 26762853

Auteurs

Alessandro Furlan (A)

UMR8161 CNRS/University of Lille/Pasteur Institute of Lille, Biology Institute of Lille, F-59021 Lille CEDEX, France.

Chantal Vercamer (C)

UMR8161 CNRS/University of Lille/Pasteur Institute of Lille, Biology Institute of Lille, F-59021 Lille CEDEX, France.

Laurent Heliot (L)

UMR8523 PhLAM, CNRS/University of Lille, 59655 Villeneuve d'Ascq CEDEX, France.

Nicolas Wernert (N)

Institute of Pathology, University of Bonn, 53011 Bonn, Germany.

Xavier Desbiens (X)

UMR8161 CNRS/University of Lille/Pasteur Institute of Lille, Biology Institute of Lille, F-59021 Lille CEDEX, France.

Albin Pourtier (A)

UMR8161 CNRS/University of Lille/Pasteur Institute of Lille, Biology Institute of Lille, F-59021 Lille CEDEX, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH